European journal of pharmacology
Nakatani Y, Amano T.
PMID: 34280395
Eur J Pharmacol. 2021 Oct 05;908:174316. doi: 10.1016/j.ejphar.2021.174316. Epub 2021 Jul 16.
Citalopram, a selective serotonin reuptake inhibitor (SSRI), has been reported to have adverse effects such as cardiotoxicity, including prolongation of the QTc interval. Although citalopram is well known to be a racemic compound comprised of S-citalopram (escitalopram) and R-citalopram,...
Cite
Nakatani Y, Amano T. Contributions of S- and R-citalopram to the citalopram-induced modulation of the function of Nav1.5 voltage-gated sodium channels. Eur J Pharmacol. 2021;908:174316doi: 10.1016/j.ejphar.2021.174316.
Nakatani, Y., & Amano, T. (2021). Contributions of S- and R-citalopram to the citalopram-induced modulation of the function of Nav1.5 voltage-gated sodium channels. European journal of pharmacology, 908174316. https://doi.org/10.1016/j.ejphar.2021.174316
Nakatani, Yoshihiko, and Amano, Taku. "Contributions of S- and R-citalopram to the citalopram-induced modulation of the function of Nav1.5 voltage-gated sodium channels." European journal of pharmacology vol. 908 (2021): 174316. doi: https://doi.org/10.1016/j.ejphar.2021.174316
Nakatani Y, Amano T. Contributions of S- and R-citalopram to the citalopram-induced modulation of the function of Nav1.5 voltage-gated sodium channels. Eur J Pharmacol. 2021 Oct 05;908:174316. doi: 10.1016/j.ejphar.2021.174316. Epub 2021 Jul 16. PMID: 34280395.
Copy
Download .nbib
